<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li DH</submitter><funding>National Natural Science Foundation of China</funding><pagination>25-30</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4448478</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>A neuroendocrine tumor (NET) is a special kind of epithelial tumor with predominant neuroendocrine differentiation, which arises throughout the body, including the lung. A subpopulation of lung cancer patients suffer from the mixed (combined) form of NET with components of non-neuroendocrine carcinoma. However, the clinical characteristics of the mixed form of NET are not well established.&lt;h4>Methods&lt;/h4>We analyzed 2501 consecutive cases of primary lung cancer from 2009 to 2011. The diagnosis, histology, therapy, and outcome were collected.&lt;h4>Results&lt;/h4>A total of 22 patients were enrolled. The occurrence rate of lung cancer was 0.9%. Neither gender (1.2% and 0.3% for male and female, respectively, P = 0.35) nor age (0.6% and 1.3% for patients aged ≤60 and >60, respectively, P = 0.13) was associated with the onset of this disease; however it has become more frequent in recent years (0.6% and 1.6% at the time ≤ and >2010 respectively, P = 0.03). This cohort of 22 patients had a median survival of 60.0 months (95% confidence interval: 14.3-105.6 months). Patients with metastatic disease (60 months and not reached [NR], P = 0.18) or a small-cell lung cancer component tended to have a shorter survival (35 months and NR, P = 0.16). Patients who underwent surgery had a significantly longer survival period (NR and 17.0 months, P = 0.001).&lt;h4>Conclusions&lt;/h4>A mixed form of NET in the lung is a rare disease. While stage and histology might influence prognosis, surgery is the critical factor for long-term survival.</pubmed_abstract><journal>Thoracic cancer</journal><pubmed_title>Clinical characteristics of the mixed form of neuroendocrine tumor in the lung: A retrospective study in 2501 lung cancer cases.</pubmed_title><pmcid>PMC4448478</pmcid><funding_grant_id>81272684</funding_grant_id><pubmed_authors>Ding ZY</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Huang H</pubmed_authors><pubmed_authors>Li DH</pubmed_authors><pubmed_authors>Chen HJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical characteristics of the mixed form of neuroendocrine tumor in the lung: A retrospective study in 2501 lung cancer cases.</name><description>&lt;h4>Background&lt;/h4>A neuroendocrine tumor (NET) is a special kind of epithelial tumor with predominant neuroendocrine differentiation, which arises throughout the body, including the lung. A subpopulation of lung cancer patients suffer from the mixed (combined) form of NET with components of non-neuroendocrine carcinoma. However, the clinical characteristics of the mixed form of NET are not well established.&lt;h4>Methods&lt;/h4>We analyzed 2501 consecutive cases of primary lung cancer from 2009 to 2011. The diagnosis, histology, therapy, and outcome were collected.&lt;h4>Results&lt;/h4>A total of 22 patients were enrolled. The occurrence rate of lung cancer was 0.9%. Neither gender (1.2% and 0.3% for male and female, respectively, P = 0.35) nor age (0.6% and 1.3% for patients aged ≤60 and >60, respectively, P = 0.13) was associated with the onset of this disease; however it has become more frequent in recent years (0.6% and 1.6% at the time ≤ and >2010 respectively, P = 0.03). This cohort of 22 patients had a median survival of 60.0 months (95% confidence interval: 14.3-105.6 months). Patients with metastatic disease (60 months and not reached [NR], P = 0.18) or a small-cell lung cancer component tended to have a shorter survival (35 months and NR, P = 0.16). Patients who underwent surgery had a significantly longer survival period (NR and 17.0 months, P = 0.001).&lt;h4>Conclusions&lt;/h4>A mixed form of NET in the lung is a rare disease. While stage and histology might influence prognosis, surgery is the critical factor for long-term survival.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Jan</publication><modification>2025-04-18T16:39:50.693Z</modification><creation>2019-03-27T01:52:22Z</creation></dates><accession>S-EPMC4448478</accession><cross_references><pubmed>26273331</pubmed><doi>10.1111/1759-7714.12128</doi></cross_references></HashMap>